Cabaletta Bio, Inc. (CABA)

Market Cap	94.89M
Revenue (ttm)	n/a
Net Income (ttm)	-126.76M
Shares Out	50.74M
EPS (ttm)	-2.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,028,262
Open	1.900
Previous Close	1.910
Day's Range	1.815 - 1.990
52-Week Range	0.986 - 13.500
Beta	2.72
Analysts	Strong Buy
Price Target	20.33 (+987.17%)
Earnings Date	May 15, 2025

About CABA

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with autoimmune diseases. Its lead product candidate is resecabtagene autoleucel, a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T, which is in Phase 1/2 clinical trials for the treatment of dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, juvenile myositis, lupus nephritis, non-renal systemic lupus erythematosus, relapsing and progressive multiple sclero...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 25, 2019
• Employees: 164
• Stock Exchange: NASDAQ
• Ticker Symbol: CABA
• Website: https://www.cabalettabio.com

Analyst Forecast

According to 9 analysts, the average rating for CABA stock is "Strong Buy." The 12-month stock price forecast is $20.33, which is an increase of 987.17% from the latest price.

Price Target

$20.33

(987.17% upside)

Analyst Consensus: Strong Buy